Citigroup
AQST icon

Citigroup’s Aquestive Therapeutics AQST Stock Holding History

Citigroup’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$174K Sell
41,907
-9,623
-19% -$39.1K ﹤0.01% 4062
2025
Q4 		$333K Buy
51,530
+46,972
+1,031% +$293K ﹤0.01% 3766
2025
Q3 		$25.5K Sell
4,558
-26,770
-85% -$116K ﹤0.01% 4734
2025
Q2 		$104K Sell
31,328
-21,836
-41% -$62.6K ﹤0.01% 4385
2025
Q1 		$154K Sell
53,164
-5,206
-9% -$15.8K ﹤0.01% 4337
2024
Q4 		$208K Buy
58,370
+1,974
+4% +$9.1K ﹤0.01% 4390
2024
Q3 		$281K Buy
56,396
+39,865
+241% +$155K ﹤0.01% 4112
2024
Q2 		$43K Sell
16,531
-34,692
-68% -$116K ﹤0.01% 4675
2024
Q1 		$218K Sell
51,223
-30,954
-38% -$103K ﹤0.01% 3979
2023
Q4 		$166K Buy
+82,177
New +$145K ﹤0.01% 3996
2022
Q4 		– Sell
-410
Closed – – 5767
2022
Q3 		$0 Sell
410
-181
-31% -$205 ﹤0.01% 5807
2022
Q2 		$0 Sell
591
-251
-30% -$334 ﹤0.01% 6214
2022
Q1 		$2K Sell
842
-348
-29% -$1.02K ﹤0.01% 6037
2021
Q4 		$5K Buy
+1,190
New +$5.97K ﹤0.01% 5654
2021
Q3 		– Sell
-1
Closed – – 5747
2021
Q2 		$0 Sell
1
-1,314
-100% -$5.25K ﹤0.01% 6114
2021
Q1 		$7K Sell
1,315
-8,823
-87% -$46.9K ﹤0.01% 5796
2020
Q4 		$54K Buy
10,138
+8,183
+419% +$49K ﹤0.01% 5969
2020
Q3 		$9K Sell
1,955
-1,665
-46% -$10.9K ﹤0.01% 6668
2020
Q2 		$18K Buy
3,620
+46
+1% +$212 ﹤0.01% 6679
2020
Q1 		$8K Buy
3,574
+2,965
+487% +$11.3K ﹤0.01% 7111
2019
Q4 		$4K Sell
609
-49
-7% -$255 ﹤0.01% 7439
2019
Q3 		$2K Sell
658
-359
-35% -$1.34K ﹤0.01% 7519
2019
Q2 		$4K Sell
1,017
-2,645
-72% -$13.5K ﹤0.01% 7513
2019
Q1 		$25K Buy
3,662
+2,785
+318% +$19.5K ﹤0.01% 6827
2018
Q4 		$6K Sell
877
-583
-40% -$7.36K ﹤0.01% 7292
2018
Q3 		$26K Buy
+1,460
New +$24.1K ﹤0.01% 6952

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's AQST Position: Q1 2026 in Review

Citigroup reduced its Aquestive Therapeutics (AQST) stake by 19% in Q1 2026, selling an estimated $39.1K and leaving 41,907 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #4062.

Citigroup first reported a position in AQST in Q3 2018 and has held it in 26 quarters since. The position peaked at $333K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Citigroup held 41,907 shares of Aquestive Therapeutics worth $174K as of Q1 2026.
  • Citigroup sold 9,623 Aquestive Therapeutics shares in Q1 2026, an estimated $39.1K.
  • Aquestive Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4062 holding.
  • Citigroup first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 26 quarters since.
  • Citigroup's Aquestive Therapeutics position peaked at $333K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.